Sage/Biogen’s zuranolone works in depression, but maybe not enoughSage Therapeutics and Biogen’s antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a Share XSage/Biogen’s zuranolone works in depression, but maybe not enoughhttps://pharmaphorum.com/news/sage-biogens-zuranolone-works-in-depression-but-maybe-not-enough/
Aduhelm approval could signal new era for CNS drugs; analystsThe unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the Share XAduhelm approval could signal new era for CNS drugs; analystshttps://pharmaphorum.com/news/aduhelm-approval-could-signal-new-era-for-cns-drugs-analysts/
Study finds “alarming” hike in antidepressant costs during COVID-19Researchers in the UK have found that there was a four million rise in prescriptions for antidepressants in Share XStudy finds “alarming” hike in antidepressant costs during COVID-19https://pharmaphorum.com/news/study-finds-alarming-hike-in-antidepressant-costs-during-covid-19/
After FDA approval, Alkermes plans soft launch for antipsychotic LybalviThe FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but Share XAfter FDA approval, Alkermes plans soft launch for antipsychotic Lybalvihttps://pharmaphorum.com/news/after-fda-approval-alkermes-plans-soft-launch-for-antipsychotic-lybalvi/
Tribunal maintains Lexon’s £1.2m fine for breaking competition lawPharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused Share XTribunal maintains Lexon’s £1.2m fine for breaking competition lawhttps://pharmaphorum.com/news/tribunal-maintains-lexons-1-2m-fine-for-breaking-competition-law/
US eyes permanent change to digital health regulatory pathDevelopers of digital health tools have benefited from a truncated route to market during the COVID-19 crisis, and Share XUS eyes permanent change to digital health regulatory pathhttps://pharmaphorum.com/news/us-eyes-permanent-change-to-digital-health-regulatory-path/
Biogen bulks up pipeline with Sage drugs in $3bn dealWith the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore Share XBiogen bulks up pipeline with Sage drugs in $3bn dealhttps://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/
Blue Oak taps AI specialist Exscientia for CNS drug discoveryUS startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK Share XBlue Oak taps AI specialist Exscientia for CNS drug discoveryhttps://pharmaphorum.com/news/blue-oak-taps-ai-specialist-exscientia-for-cns-drug-discovery/
Pear rolls out digital therapy for schizophrenia under FDA’s COVID-19 schemePear Therapeutics has started a limited launch of its digital therapeutic for people living with schizophrenia under the Share XPear rolls out digital therapy for schizophrenia under FDA’s COVID-19 schemehttps://pharmaphorum.com/news/pear-rolls-out-digital-therapy-for-schizophrenia-under-fdas-covid-19-scheme/
